JP2022514344A5 - - Google Patents
Info
- Publication number
- JP2022514344A5 JP2022514344A5 JP2021535539A JP2021535539A JP2022514344A5 JP 2022514344 A5 JP2022514344 A5 JP 2022514344A5 JP 2021535539 A JP2021535539 A JP 2021535539A JP 2021535539 A JP2021535539 A JP 2021535539A JP 2022514344 A5 JP2022514344 A5 JP 2022514344A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024083009A JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782298P | 2018-12-19 | 2018-12-19 | |
| US62/782,298 | 2018-12-19 | ||
| US201962879900P | 2019-07-29 | 2019-07-29 | |
| US62/879,900 | 2019-07-29 | ||
| PCT/US2019/067088 WO2020132014A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083009A Division JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022514344A JP2022514344A (ja) | 2022-02-10 |
| JPWO2020132014A5 JPWO2020132014A5 (https=) | 2023-01-20 |
| JP2022514344A5 true JP2022514344A5 (https=) | 2023-01-20 |
| JP7494181B2 JP7494181B2 (ja) | 2024-06-03 |
Family
ID=71098067
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535539A Active JP7494181B2 (ja) | 2018-12-19 | 2019-12-18 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
| JP2024083009A Active JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083009A Active JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US11149007B2 (https=) |
| EP (2) | EP4494711A3 (https=) |
| JP (2) | JP7494181B2 (https=) |
| KR (2) | KR20250144505A (https=) |
| CN (2) | CN113453681B (https=) |
| AU (1) | AU2019403207B2 (https=) |
| BR (1) | BR112021011968A2 (https=) |
| CA (1) | CA3124130A1 (https=) |
| CL (1) | CL2021001665A1 (https=) |
| CO (1) | CO2021007973A2 (https=) |
| DK (1) | DK3897636T3 (https=) |
| ES (1) | ES3009308T3 (https=) |
| FI (1) | FI3897636T3 (https=) |
| HR (1) | HRP20250095T1 (https=) |
| HU (1) | HUE070506T2 (https=) |
| IL (1) | IL284223B2 (https=) |
| LT (1) | LT3897636T (https=) |
| MX (1) | MX2021007473A (https=) |
| MY (1) | MY205718A (https=) |
| PE (1) | PE20212247A1 (https=) |
| PL (1) | PL3897636T3 (https=) |
| PT (1) | PT3897636T (https=) |
| RS (1) | RS66556B1 (https=) |
| SG (1) | SG11202106507RA (https=) |
| SI (1) | SI3897636T1 (https=) |
| SM (1) | SMT202500111T1 (https=) |
| TW (1) | TWI820276B (https=) |
| WO (1) | WO2020132014A1 (https=) |
| ZA (1) | ZA202104200B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3897636T3 (pl) * | 2018-12-19 | 2025-04-28 | Celgene Corporation | Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi |
| US11325889B2 (en) * | 2018-12-19 | 2022-05-10 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| PE20231746A1 (es) * | 2020-06-24 | 2023-11-06 | Celgene Corp | Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| WO2022019597A1 (ko) * | 2020-07-21 | 2022-01-27 | 주식회사 유빅스테라퓨틱스 | 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도 |
| WO2022061348A1 (en) | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| TW202237580A (zh) | 2020-12-14 | 2022-10-01 | 美商拜歐斯瑞克斯公司 | Pde4降解劑、醫藥組合物及治療應用 |
| TWI807697B (zh) * | 2021-03-17 | 2023-07-01 | 大陸商南京明德新藥研發有限公司 | 呋喃稠環取代的戊二醯亞胺類化合物 |
| EP4359407A4 (en) * | 2021-06-25 | 2025-04-30 | Celgene Corporation | CEREBLON-BINDING COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT USING THEM |
| EP4359404A4 (en) * | 2021-06-25 | 2025-06-04 | Celgene Corporation | Cereblon-binding compounds, compositions thereof and methods of treatment therewith |
| JP2024526192A (ja) * | 2021-06-25 | 2024-07-17 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| WO2024102706A1 (en) * | 2022-11-09 | 2024-05-16 | Bristol-Myers Squibb Company | Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds |
| US12496301B2 (en) | 2023-12-08 | 2025-12-16 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| US20250346577A1 (en) * | 2024-05-07 | 2025-11-13 | Bristol-Myers Squibb Company | Processes for the preparation of substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds |
| WO2025235577A1 (en) * | 2024-05-09 | 2025-11-13 | Bristol-Myers Squibb Company | Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds |
| CN118993935B (zh) * | 2024-10-23 | 2025-02-14 | 江苏恒瑞医药股份有限公司 | 咪唑啉衍生物或其盐的制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| FR2768729A1 (fr) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique et complexes catalytiques |
| FR2768728B1 (fr) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| TW200621723A (en) * | 2004-09-09 | 2006-07-01 | Chugai Pharmaceutical Co Ltd | Novel imidazolidine derivative and use thereof |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| WO2007136640A2 (en) * | 2006-05-16 | 2007-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| JP2012532929A (ja) | 2009-07-13 | 2012-12-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二機能性のステープリングされたポリペプチドおよびそれらの使用 |
| RU2434851C1 (ru) * | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| DK2683694T3 (en) * | 2011-03-10 | 2016-07-18 | Suzhou Kintor Pharmaceuticals Inc | ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| RS61242B1 (sr) * | 2012-09-04 | 2021-01-29 | Shanghai hengrui pharmaceutical co ltd | Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US10730870B2 (en) | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017011371A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3481394A1 (en) * | 2016-07-08 | 2019-05-15 | Janssen Pharmaceutica N.V. | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| TWI739888B (zh) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | 農藥組合物及方法 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US10925868B2 (en) | 2016-11-10 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| CA3042301A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| DK3524603T3 (da) | 2016-12-19 | 2022-07-04 | Abbisko Therapeutics Co Ltd | Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN109422725A (zh) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| ES2959954T3 (es) | 2017-11-28 | 2024-02-29 | Aarti Pharmalabs Ltd | Proceso para la preparación de enzalutamida utilizando un nuevo intermedio |
| CN111163638B (zh) | 2017-12-05 | 2023-07-25 | 美国陶氏益农公司 | 杀有害生物组合物和方法 |
| CA3101227A1 (en) | 2018-05-30 | 2019-12-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof |
| CN109651256A (zh) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| PL3897636T3 (pl) * | 2018-12-19 | 2025-04-28 | Celgene Corporation | Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi |
| US11325889B2 (en) * | 2018-12-19 | 2022-05-10 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
-
2019
- 2019-12-18 PL PL19901383.0T patent/PL3897636T3/pl unknown
- 2019-12-18 CN CN201980092358.2A patent/CN113453681B/zh active Active
- 2019-12-18 MY MYPI2021003454A patent/MY205718A/en unknown
- 2019-12-18 FI FIEP19901383.0T patent/FI3897636T3/fi active
- 2019-12-18 KR KR1020257032139A patent/KR20250144505A/ko active Pending
- 2019-12-18 DK DK19901383.0T patent/DK3897636T3/da active
- 2019-12-18 SI SI201930889T patent/SI3897636T1/sl unknown
- 2019-12-18 PT PT199013830T patent/PT3897636T/pt unknown
- 2019-12-18 PE PE2021000924A patent/PE20212247A1/es unknown
- 2019-12-18 HU HUE19901383A patent/HUE070506T2/hu unknown
- 2019-12-18 SG SG11202106507RA patent/SG11202106507RA/en unknown
- 2019-12-18 US US16/719,171 patent/US11149007B2/en active Active
- 2019-12-18 EP EP24218737.5A patent/EP4494711A3/en active Pending
- 2019-12-18 IL IL284223A patent/IL284223B2/en unknown
- 2019-12-18 EP EP19901383.0A patent/EP3897636B1/en active Active
- 2019-12-18 LT LTEPPCT/US2019/067088T patent/LT3897636T/lt unknown
- 2019-12-18 AU AU2019403207A patent/AU2019403207B2/en active Active
- 2019-12-18 ES ES19901383T patent/ES3009308T3/es active Active
- 2019-12-18 SM SM20250111T patent/SMT202500111T1/it unknown
- 2019-12-18 KR KR1020217019479A patent/KR102866144B1/ko active Active
- 2019-12-18 RS RS20250148A patent/RS66556B1/sr unknown
- 2019-12-18 BR BR112021011968-0A patent/BR112021011968A2/pt unknown
- 2019-12-18 CA CA3124130A patent/CA3124130A1/en active Pending
- 2019-12-18 MX MX2021007473A patent/MX2021007473A/es unknown
- 2019-12-18 WO PCT/US2019/067088 patent/WO2020132014A1/en not_active Ceased
- 2019-12-18 JP JP2021535539A patent/JP7494181B2/ja active Active
- 2019-12-18 TW TW108146514A patent/TWI820276B/zh active
- 2019-12-18 CN CN202411325996.3A patent/CN119219606A/zh active Pending
- 2019-12-18 HR HRP20250095TT patent/HRP20250095T1/hr unknown
-
2021
- 2021-06-18 ZA ZA2021/04200A patent/ZA202104200B/en unknown
- 2021-06-18 CO CONC2021/0007973A patent/CO2021007973A2/es unknown
- 2021-06-18 CL CL2021001665A patent/CL2021001665A1/es unknown
- 2021-08-16 US US17/403,742 patent/US11873283B2/en active Active
-
2023
- 2023-11-28 US US18/521,663 patent/US12404241B2/en active Active
-
2024
- 2024-05-22 JP JP2024083009A patent/JP7724911B2/ja active Active